Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Moderate Buy” by the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $68.6667.
A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Guggenheim lowered their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. HC Wainwright cut their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. JMP Securities reduced their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd.
Read Our Latest Stock Analysis on GPCR
Institutional Investors Weigh In On Structure Therapeutics
Structure Therapeutics Stock Performance
Structure Therapeutics stock opened at $27.38 on Friday. The company has a market capitalization of $1.58 billion, a PE ratio of -26.08 and a beta of -1.65. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $42.57. The firm has a 50 day moving average price of $22.99 and a 200 day moving average price of $21.59.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, equities research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.
Structure Therapeutics Company Profile
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Read More
- Five stocks we like better than Structure Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- This AI Chip Giant Could Be the Market’s Next Big Winner
- How to Short Nasdaq: An Easy-to-Follow Guide
- Broadcom Inks OpenAI Deal: Why It’s A Huge Win for AVGO Stock
- What is the Dogs of the Dow Strategy? Overview and Examples
- Institutions Are Fueling CrowdStrike’s Next Leg Higher
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.